GB0308333D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0308333D0
GB0308333D0 GBGB0308333.4A GB0308333A GB0308333D0 GB 0308333 D0 GB0308333 D0 GB 0308333D0 GB 0308333 A GB0308333 A GB 0308333A GB 0308333 D0 GB0308333 D0 GB 0308333D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0308333.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0308333.4A priority Critical patent/GB0308333D0/en
Publication of GB0308333D0 publication Critical patent/GB0308333D0/en
Priority to ARP040101188A priority patent/AR044006A1/es
Priority to RU2005134006/04A priority patent/RU2005134006A/ru
Priority to DE602004007119T priority patent/DE602004007119T2/de
Priority to US10/551,985 priority patent/US20060205774A1/en
Priority to TW093109666A priority patent/TW200503710A/zh
Priority to PCT/EP2004/003985 priority patent/WO2004089373A1/en
Priority to ES04726514T priority patent/ES2288681T3/es
Priority to AU2004228949A priority patent/AU2004228949B2/en
Priority to BRPI0409110-8A priority patent/BRPI0409110A/pt
Priority to JP2006505136A priority patent/JP2006522771A/ja
Priority to KR1020057019137A priority patent/KR20050111638A/ko
Priority to AT04726514T priority patent/ATE365039T1/de
Priority to CA002521899A priority patent/CA2521899A1/en
Priority to CNA2004800161953A priority patent/CN1805747A/zh
Priority to EP04726514A priority patent/EP1610786B9/en
Priority to MXPA05010816A priority patent/MXPA05010816A/es
Priority to ZA200507795A priority patent/ZA200507795B/en
Priority to CO05101708A priority patent/CO5640135A2/es
Priority to US11/246,480 priority patent/US20060293298A1/en
Priority to MA28548A priority patent/MA27726A1/fr
Priority to IS8118A priority patent/IS8118A/is
Priority to NO20055256A priority patent/NO20055256L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0308333.4A 2003-04-10 2003-04-10 Novel compounds Ceased GB0308333D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB0308333.4A GB0308333D0 (en) 2003-04-10 2003-04-10 Novel compounds
ARP040101188A AR044006A1 (es) 2003-04-10 2004-04-07 Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
MXPA05010816A MXPA05010816A (es) 2003-04-10 2004-04-08 Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer.
JP2006505136A JP2006522771A (ja) 2003-04-10 2004-04-08 アルツハイマーなどの神経疾患の治療用のヒスタミンｈ３アンタゴニストとしての４−（４−｛ヘテロサイクリルアルコキシ｝フェニル）−１−（ヘテロサイクリル−カルボニル）ピペリジン誘導体およびその関連化合物
CA002521899A CA2521899A1 (en) 2003-04-10 2004-04-08 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases suchas alzheimer's
US10/551,985 US20060205774A1 (en) 2003-04-10 2004-04-08 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's
TW093109666A TW200503710A (en) 2003-04-10 2004-04-08 Novel compounds
PCT/EP2004/003985 WO2004089373A1 (en) 2003-04-10 2004-04-08 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer’s
ES04726514T ES2288681T3 (es) 2003-04-10 2004-04-08 Derivados de 4-(4-heterociclilalcoxifenil)-1-(heterociclilcarbonil)piperidina y compuestos relacionados como antagonistas de h3 de histamina para el tratamiento de enfermedades neurologicas tales como alzheimer.
AU2004228949A AU2004228949B2 (en) 2003-04-10 2004-04-08 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine H3 antagonists for the treatment of neurological diseases such as Alzheimer's
BRPI0409110-8A BRPI0409110A (pt) 2003-04-10 2004-04-08 derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
RU2005134006/04A RU2005134006A (ru) 2003-04-10 2004-04-08 Производные 4-(4-{гетероциклилалкокси}фенил0-1-(гетероциклилкарбонил)пиперидина и родственные соединения как антагонисты гистамина н3 для лечения неврологических заболеваний, таких как болезнь альцгеймера
KR1020057019137A KR20050111638A (ko) 2003-04-10 2004-04-08 알츠하이머병을 비롯한 신경계 질환의 치료를 위한히스타민 ｈ3 길항제로서의4-(4-(헤테로시클릴알콕시)페닐)-1-(헤테로시클릴-카르보닐)피페리딘 유도체 및 관련 화합물
AT04726514T ATE365039T1 (de) 2003-04-10 2004-04-08 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's
DE602004007119T DE602004007119T2 (de) 2003-04-10 2004-04-08 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's
CNA2004800161953A CN1805747A (zh) 2003-04-10 2004-04-08 4－( 4－(杂环基烷氧基 )苯基)－1－(杂环基－羰基)哌啶衍生物和相关的化合物作为组胺h3拮抗剂用于治疗神经疾病如阿尔茨海默氏病
EP04726514A EP1610786B9 (en) 2003-04-10 2004-04-08 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's
ZA200507795A ZA200507795B (en) 2003-04-10 2005-09-27 4-(4-Heterocyclylalkoxy)phenyl)-1-(heterocyclyl-carbonyl) piperidine derivatives and related compounds as histamine H3 antagonists for the treatment of neurological diseases such as Alzheimer's
CO05101708A CO5640135A2 (es) 2003-04-10 2005-10-06 Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer
US11/246,480 US20060293298A1 (en) 2003-04-10 2005-10-07 Compounds
MA28548A MA27726A1 (fr) 2003-04-10 2005-10-11 Derives de 4-(4-(heterocyclylalkoxy)phenyl-1-(heterocyclyl-carbonyl) piperidine et composes associes servant d'antagonistes d'histamine h3 destines au traitement de troubles neurologiques
IS8118A IS8118A (is) 2003-04-10 2005-11-08 4-(4-(heterósýklýlalkoxý)fenýl}-1-(heterósýklýl-karbónýl)píperídínafleiður og skyld efnasambönd semhistamín H3 mótlyf til að meðhöndla taugasjúkdómaeins og Alzheimerssjúkdóm
NO20055256A NO20055256L (no) 2003-04-10 2005-11-09 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308333.4A GB0308333D0 (en) 2003-04-10 2003-04-10 Novel compounds

Publications (1)

Publication Number Publication Date
GB0308333D0 true GB0308333D0 (en) 2003-05-14

Family

ID=9956580

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0308333.4A Ceased GB0308333D0 (en) 2003-04-10 2003-04-10 Novel compounds

Country Status (22)

Country Link
US (1) US20060205774A1 (https=)
EP (1) EP1610786B9 (https=)
JP (1) JP2006522771A (https=)
KR (1) KR20050111638A (https=)
CN (1) CN1805747A (https=)
AR (1) AR044006A1 (https=)
AT (1) ATE365039T1 (https=)
AU (1) AU2004228949B2 (https=)
BR (1) BRPI0409110A (https=)
CA (1) CA2521899A1 (https=)
CO (1) CO5640135A2 (https=)
DE (1) DE602004007119T2 (https=)
ES (1) ES2288681T3 (https=)
GB (1) GB0308333D0 (https=)
IS (1) IS8118A (https=)
MA (1) MA27726A1 (https=)
MX (1) MXPA05010816A (https=)
NO (1) NO20055256L (https=)
RU (1) RU2005134006A (https=)
TW (1) TW200503710A (https=)
WO (1) WO2004089373A1 (https=)
ZA (1) ZA200507795B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7553964B2 (en) * 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
EP1896453B1 (en) 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP4860700B2 (ja) 2005-09-20 2012-01-25 シェーリング コーポレイション ヒスタミンＨ３アンタゴニストとして有用な、１−［［１−［（２−アミノ−６−メチル−４−ピリジニル）メチル］−４−フルオロ−４−ピペリジニル］カルボニル］−４−［２−（２−ピリジニル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−３−イル］ピペリジン
CA2627234A1 (en) 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
TW200730498A (en) * 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
MX2008008339A (es) 2005-12-21 2008-09-03 Schering Corp Derivados de anilina sustituida ùtiles como antagonistas de la histamina h3.
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2124933B1 (en) * 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
MX2010013876A (es) * 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN109674753A (zh) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 固态分散体
EP2789608A4 (en) 2011-12-08 2015-07-01 Taisho Pharmaceutical Co Ltd PHENYLPYRROLDERIVAT
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6801159B2 (ja) 2015-04-21 2020-12-16 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． イミダゾイソインドール誘導体、その製造方法及びその医薬用途
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2020179780A1 (ja) * 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DE4407139A1 (de) * 1994-03-04 1995-09-07 Thomae Gmbh Dr K Aryl-1-azacycloalkane und deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
CA2214288C (en) * 1996-09-18 2006-07-18 Lonza Ag Process for the preparation of 1-acyl-4-arylpiperidines
EP0837065A1 (de) * 1996-10-16 1998-04-22 Ciba SC Holding AG Phenylglycidylether-HALS
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
BR0108088A (pt) * 2000-07-13 2004-04-06 Abbott Lab Pirrolidinas 1,3-dissubstituìdas e 1,3,3-trissubstituìdas como ligandos receptores de histamina-3 e suas aplicações terapêuticas
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
IL157253A0 (en) * 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases

Also Published As

Publication number Publication date
ES2288681T3 (es) 2008-01-16
EP1610786B9 (en) 2008-02-27
AU2004228949B2 (en) 2006-11-02
NO20055256D0 (no) 2005-11-09
EP1610786A1 (en) 2006-01-04
JP2006522771A (ja) 2006-10-05
CN1805747A (zh) 2006-07-19
ZA200507795B (en) 2006-07-26
MA27726A1 (fr) 2006-01-02
EP1610786B1 (en) 2007-06-20
RU2005134006A (ru) 2006-04-10
CO5640135A2 (es) 2006-05-31
KR20050111638A (ko) 2005-11-25
ATE365039T1 (de) 2007-07-15
DE602004007119D1 (de) 2007-08-02
DE602004007119T2 (de) 2008-02-21
AU2004228949A1 (en) 2004-10-21
MXPA05010816A (es) 2005-12-05
NO20055256L (no) 2006-01-10
TW200503710A (en) 2005-02-01
CA2521899A1 (en) 2004-10-21
IS8118A (is) 2005-11-08
BRPI0409110A (pt) 2006-03-28
AR044006A1 (es) 2005-08-24
US20060205774A1 (en) 2006-09-14
WO2004089373A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
GB0308114D0 (en) Novel compounds
GB0305918D0 (en) Novel compounds
GB0308186D0 (en) Novel compounds
GB0308185D0 (en) Novel compounds
GB0304424D0 (en) Novel compounds
GB0308333D0 (en) Novel compounds
EP1596860A4 (en) NEW CONNECTIONS
EP1648885A4 (en) NEW CONNECTIONS
GB0305426D0 (en) Novel compounds
GB0302431D0 (en) Novel compounds
GB0304809D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
GB0304803D0 (en) Novel compounds
GB0305293D0 (en) Novel compounds
GB0301872D0 (en) Novel compounds
GB0301608D0 (en) Novel compounds
GB0302988D0 (en) Novel compounds
GB0303464D0 (en) Novel compounds
GB0303467D0 (en) Novel compounds
GB0304408D0 (en) Novel compounds
GB0301593D0 (en) Novel compounds
GB0304802D0 (en) Novel compounds
GB0301592D0 (en) Novel compounds
GB0301591D0 (en) Novel compounds
GB0304811D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)